Royalty Pharma Q3 2025 Earnings Call: Portfolio Growth, Strong Returns, and Expanded Pipeline

Royalty Pharma PLC reported an 11% growth in both portfolio and royalty receipts, driven by a strong diversified portfolio. The company raised its full-year 2025 topline guidance to $3.2 billion to $3.25 billion and expanded its development stage pipeline to 17 therapies. However, it faces competition from follow-on therapies and expects minimal royalties from Promacta next year. Operating and professional costs are expected to be higher due to one-time expenses.